Loading clinical trials...

Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies

Study of the Interest of the Combination of Stiripentol (Diacomit®) and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies

NCT05419180•Biocodex

View on ClinicalTrials.gov

Summary

This is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combination of stiripentol (Diacomit®) and Carbamazepine.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Retrospective part of the research:
•The medical records of CRéER patients with the following criteria will be included in the retrospective part of the research by an investigator:
•1. With pharmacoresistant epilepsy, i.e. a history of failure of two well-conducted and well-tolerated antiepileptic treatment regimens, either as monotherapy or as combination therapy,
•2. Receiving or having received a treatment combining stiripentol and carbamazepine for a period of at least 15 days,
•3. Having at least one evaluation data after the initiation of treatment with stiripentol and carbamazepine (a follow-up visit after the initiation of the study treatment),
•4. For which an information note indicating the possibility of opposing the processing of data has been provided.
•* Prospective part of the research:
•Among the patients whose medical records are included in the retrospective part of the research, those who meet the following criteria will be able to participate in the prospective part of the research:
•1. Currently treated with stiripentol in combination with carbamazepine for at least 15 days and still being followed in the center,
•2. Weighing at least 5 kg (minimum weight in accordance with the blood volume taken),
+3 more criteria

Exclusion Criteria

•\- Retrospective part of the research : Patients objecting to the collection of their data will not participate in the research.
•\- Prospective part of the research :
•Patients with the following criteria will not be able to participate in the prospective part of the research:
•1. Participating simultaneously in another interventional clinical trial or in a period of exclusion following a previous trial,
•2. Whose state of health does not allow him to give his consent,
•3. Under guardianship or curatorship,
•4. Under judicial protection or person deprived of liberty.

Locations (1)

Centre de Référence Epilepsies Rares / Centre Investigation Clinique (CIC) - Hôpital Necker-Enfants Malades

Paris, France

Key Dates

Start Date

October 13, 2022

Primary Completion Date

June 13, 2024

Completion Date

June 13, 2024

Last Updated

July 24, 2024

Enrollment

ACTUAL participants

Conditions

Pharmacoresistant Focal Epilepsies

Interventions

Stiripentol

DRUG